within Pharmacolibrary.Drugs.ATC.B;

model B03XA08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 0.933 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,
    adminCount     = 1,
    Vd             = 0.045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.011533333333333333,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used to treat anemia associated with chronic kidney disease (CKD). It stimulates erythropoiesis by increasing endogenous erythropoietin levels. Vadadustat has been approved in Japan and is under regulatory review or clinical use in other countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adults after single oral administration.</p><h4>References</h4><ol><li><p>Janković, SM, &amp; Janković, SV (2025). Clinical Pharmacokinetics and Pharmacodynamics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. <i>European journal of drug metabolism and pharmacokinetics</i> None –. DOI:<a href=&quot;https://doi.org/10.1007/s13318-025-00947-2&quot;>10.1007/s13318-025-00947-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/40314830/&quot;>https://pubmed.ncbi.nlm.nih.gov/40314830</a></p></li><li><p>Chavan, A, et al., &amp; Paulson, SK (2021). Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. <i>Clinical pharmacology in drug development</i> 10(8) 950–958. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.927&quot;>10.1002/cpdd.927</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33661566/&quot;>https://pubmed.ncbi.nlm.nih.gov/33661566</a></p></li><li><p>Navarro-Gonzales, P, et al., &amp; Dykstra, K (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease. <i>Clinical pharmacology and therapeutics</i> 116(4) 1052–1061. DOI:<a href=&quot;https://doi.org/10.1002/cpt.3342&quot;>10.1002/cpt.3342</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38924087/&quot;>https://pubmed.ncbi.nlm.nih.gov/38924087</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B03XA08;
